Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure.
Parenteral omega-3 fatty acid lipid emulsions have been evaluated for their potential role in reversing intestinal failure-associated liver disease. We report our experience using Omegaven in 2 patients with irreversible intestinal failure and intestinal failure-associated liver disease. Despite biochemical and histologic improvement in cholestasis, both patients had persisting, significant portal fibrosis on liver biopsy.
Soden
Jason S
JS
Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Colorado Denver School of Medicine and The Children's Hospital, 13123 E 16th Ave, Box B290, Aurora, CO 80045, USA. soden.jason@tchden.org
Lovell
Mark A
MA
Brown
Kristin
K
Partrick
David A
DA
Sokol
Ronald J
RJ
D005217:Fat Emulsions, Intravenous / Q000627:therapeutic use*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006627:Hirschsprung Disease / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D007410:Intestinal Diseases / Q000628:therapy*; D008105:Liver Cirrhosis, Biliary / Q000473:pathology / Q000628:therapy*; D008297:Male; D010288:Parenteral Nutrition / Q000009:adverse effects / Q000379:methods*; D017211:Treatment Failure
D005217:Fat Emulsions, Intravenous; D015525:Fatty Acids, Omega-3